series-c-plus
Stage
3
Investors
About
Beacon Therapeutics is an ophthalmic gene therapy company developing AAV-based treatments to restore and improve vision for patients with inherited and other retinal diseases. Its lead asset, AGTC-501 (laru-zova), is in Phase III clinical trials for X-linked retinitis pigmentosa (XLRP).
Explore Beacon Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.